Quince Therapeutics (QNCX) said late Tuesday that the enrollment in its phase 3 clinical trial of the neurological effects of eDSP system on Ataxia-Telangiectasia patients has exceeded 75%.

EDSP is comprised of dexamethasone sodium phosphate encapsulated in a patient's own red blood cells.

A total of 76 participants have been enrolled, including 65 participants in the six- to nine-year-old primary analysis population and 11 participants aged 10 years or above, the company said.

The company said it plans to submit a new drug application to the US Food and Drug Administration in H2 2026, subject to a positive outcome of the trial.

The company said it received the FDA's fast track designation for eDSP system for the treatment of patients with Ataxia-Telangiectasia, a rare neurodegenerative disease.